It is reported that, compared with the single vaccine or anti-CTLA-4 monoclonal antibody, immunotherapy combining the MUC1 mRNA nanovaccine, another kind of tumor vaccine, and anti-CTLA-4 monoclonal antibody is capable of effectively suppressing TNBC growth and significantly increasing the tumor-infiltrating CD8+T cell number. Here, CTLA4 is linked to neoplasm.